Pfizer (PFE)
(Delayed Data from NYSE)
$28.30 USD
-0.22 (-0.77%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.30 USD
-0.22 (-0.77%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Three Encouraging News on U.S. Economic Recovery: 5 Top Picks
by Nalak Das
We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.
Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track
by Zacks Equity Research
Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Nonfarm Payrolls Jump in October
by Zacks Equity Research
Nonfarm Payrolls Jump in October.
Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.
Huge Jobs Number: 531K, 4.6% Unemployment; Did Pfizer Cure Covid?
by Mark Vickery
The private sector alone brought 604K jobs, more than a third of which came from the Leisure & Hospitality and Professional & Business Services sectors.
The Zacks Analyst Blog Highlights: Nucor, Dow, Pfizer, Costco and Lowe's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nucor, Dow, Pfizer, Costco and Lowe's
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.
Fed Chair Speaks in Cautious Tone Despite Tapering: 5 Picks
by Nalak Das
Each of our large-cap picks carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy) and has a VGM Score of A. These are: NUE, PFE, DOW, COST and LOW.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
by Zacks Equity Research
Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.
Better-Than-Expected Private Payrolls in October
by Zacks Equity Research
Better-Than-Expected Private Payrolls in October.
ADP: 571K New Private-Sector Jobs, Better than Expected
by Mark Vickery
571K new private-sector jobs in October surpassed the analyst estimate of 398K by a ton.
Stock Market News for Nov 3, 2021
by Zacks Equity Research
Wall Street maintained its northbound journey on Tuesday with all three major stock indexes closed at record-high levels for three consecutive days.
Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.
5 Blue-Chip Stock to Buy as Dow Crosses a Fresh Milestone
by Nalak Das
We have narrowed down our search to five Dow stocks with strong growth potential for the ensuing quarter. These are: CVX, DOW, MCD, HD and MSFT.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2022 on the third-quarter earnings call.
Fed Set to Start Vital FOMC Meeting
by Zacks Equity Research
Fed Set to Start Vital FOMC Meeting.
Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up
by Zacks Equity Research
Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.
Fed Meets, Tapering in Our Midst; Pfizer Beats in Q3
by Mark Vickery
The question now is: when will the Fed start tapering, and by how much?
Pfizer (PFE) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 24.07% and 7.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
How Will Pfizer's (PFE) Key Drugs Impact Its Q3 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.
Stock Market News for Nov 1, 2021
by Zacks Equity Research
Wall Street closed higher on Friday despite weak earnings results of a couple of technology behemoths.